The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
AttardG., ReidA.H.M., YapT.A.Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol.2008; 26(28): 4563–4571.
2.
AttardG., ReidA.H.M., A'HernR.A.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol.2009; 27(23): 3742–3748.
3.
RyanC.J., SmithM.R., FongL.Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol.2010; 28(9): 1481–1488.
4.
ReidA.H.M., AttardG., DanilaD.C.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol.2010; 28(9): 1489–1495.
5.
DanilaD.C., MorrisM.J., de BonoJ.S.Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol.2010; 28(9): 1496–1501.
de BoerR., HumbletY., WolfJ.An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol.2009; 20(3): 486–491.
8.
NataleR.B., BodkinD., GovindanR.Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol.2009; 27(15): 2523–2529.
9.
HanrahanE.O., LinH.Y., KimE.S.Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol.2010; 28(2): 193–201.
10.
WellsS.A., GosnellJ.E., GagelR.F.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medulary thyroid cancer. J Clin Oncol.2010; 28(5): 767–772.
11.
RobinsonB.G., Paz-Ares, KrebsA.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Endocrinol Metab.2010; 95(6): 2664–2671.
12.
HerbstR.S., SunY., EberhardtW.E.E.Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomized, phase 3 trial. Lancet Oncol.2010; 11(7): 619–626.
13.
BroniscerA., BakerJ.N., TagenM.Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol.2010; 28(31): 4762–4768.
